BRANCHBURG, N.J.--(EON: Enhanced Online News)--LifeCell, a leader in the science of regenerative medicine and tissue repair products, has introduced the REVOLVE™ System to offer fast, efficient and secure fat transfer processing in a range of aesthetic and reconstructive procedures. Fat grafting involves harvesting and transferring adipose tissue or body fat from one area of the body to another. The technique is gaining in popularity with surgeons because it uses the patient’s own tissue to enhance volume.
“The use of fat grafting for breast reconstruction can help patients achieve more natural-looking breasts following lumpectomy or mastectomy”
The REVOLVE™ System is designed to yield rapid, reliable results in high-volume procedures through the use of a simple, closed system that controls critical variables in fat grafting. The single-use device can be placed in the sterile field to facilitate more efficient processing, filtering, and transferring of a patient’s own (autologous) fat tissue. It enables high-volume fat processing (up to 800ml lipoaspirate) in less than 15 minutes, offering the potential to reduce OR procedure time.
“The use of fat grafting for breast reconstruction can help patients achieve more natural-looking breasts following lumpectomy or mastectomy,” said Dr. Allen Gabriel, MD, FACS, with Peace Health Medical Group Plastic Surgery, Vancouver, WA. “We have found the REVOLVE™ System enables us to process large volumes of fat in an efficient manner and obtain a high quality graft for use in reconstructive procedures.”
REVOLVE™ uses a specially designed mesh to filter blood debris and fluid and yield high quality, clean adipose fat. A proprietary “collagen string catcher” enhances procedural speed and efficiency by helping to prevent syringe tips from clogging during fat re-implantation.
An animal study* comparing the REVOLVE™ System to fat processing done through the decant method and centrifugation showed equal or greater fat retention for REVOLVE™. The device also removed more free oil and red blood cells from the fat graft than either the decant method or centrifugation. In the same study, the fat processed with REVOLVE™ demonstrated an ability to maintain physiological conditions such as pH and osmolality.
*Correlation of these results to results in humans has not been established.
The REVOLVE™ System was developed by The GID Group, Inc., a consortium of world-leading plastic surgeons and adipose tissue scientists that use a deep science-based approach to create reliable, cost-effective tissue processing platforms. The device is marketed and sold by LifeCell Corporation.
About LifeCell Corporation
LifeCell Corporation, a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets. LifeCell products include: Strattice™ Reconstructive Tissue Matrix and AlloDerm® Regenerative Tissue Matrix, for plastic, reconstructive, and general surgical applications; Cymetra® Regenerative Tissue Matrix, a particulate form of AlloDerm® Tissue Matrix suitable for injection; Repliform® Regenerative Tissue Matrix, for urogynecologic surgical procedures; GraftJacket® and Conexa™ for orthopedic surgical procedures; and the SPY® Elite System for the visualization and evaluation of tissue perfusion.
For more information about LifeCell visit www.lifecell.com.
Fair Balance Statement:
Indications of Use
REVOLVE™ is used for aspiration, harvesting, filtering, and transferring autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is only to be used without any additional manipulation.
Intended for use in the following surgical specialties when the aspiration of soft-tissue is desired: plastic and reconstructive surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, orthopedic surgery, gynecological surgery, thoracic surgery, and laparoscopic surgery.
Contraindications to Autologous Fat Transfer include the presence of any disease processes that adversely affect wound healing, and poor overall health status of the individual.
1. This device will not, in and of itself, produce significant weight reduction.
2. This device should be used with extreme caution in patients with chronic medical conditions such as diabetes, heart, lung, or circulatory system disease or obesity.
3. The volume of blood loss and endogenous body fluid loss may adversely affect intra and/or postoperative hemodynamic stability and patient safety. The capability of providing adequate, timely replacement is essential for patient safety.
1. This device is designed to remove localized deposits of excess fat through small incision and subsequently transfer the tissue back to the patient.
2. Use of this device is limited to those physicians who, by means of formal professional training or sanctioned continuing medical education (including supervised operative experience), have attained proficiency in suction lipoplasty and tissue transfer.
3. Results of this procedure will vary depending upon patient age, surgical site, and experience of the physician.
4. Results of this procedure may or may not be permanent.
5. The amount of fat removed should be limited to that necessary to achieve a desired cosmetic effect.
Some common adverse effects associated with Autologous Fat Transfer are asymmetry, over- and/or under-correction of the treatment site, tissue lumps, bleeding, and scarring.